-Member Login

Forgot your USERNAME OR PASSWORD?

Job Postings

Let's Stay Connected

Find us on the popular social networks

Facebook Twitter LinkedIn Flicker

Journal Highlights

DMD Highlight: Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors

Posted on 1/23/2017 1:28:40 PM

DMD Highlights January Scheible et al
 

Pimasertib is a selective inhibitor of MEK1/2, which is often dysregulated in cancer cells, and its clinical activity is being investigated in various tumor types. In a phase I mass balance study, one of the two major metabolites in urine was a phosphoethanolamine conjugate on the propanediol moiety. Phosphoethanolamine conjugates of any drug have not been reported previously, and studies of the enzymes involving their generation are ongoing.

See the article by Scheible et al. at Drug Metabolism and Disposition February 2017, 45 (2) 174-182; DOI: https://doi.org/10.1124/dmd.116.072934 

Comments (0)


Leave a comment


Blog comments are moderated and will be posted once approved.

Name


Comment:


Enter the code shown below:

Recent Posts

Archive

.

Hot Links 

Advertise in Explore Pharmacology 2017 

2017 Award Nominations Side 

Join ASPET 

What is Pharmacology? Video 

PharmTalk Blog